AI could predict who lives longer after lung cancer immunotherapy

NCT ID NCT07668037

Recruiting now Knowledge-focused Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope images, potentially helping doctors personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a tool that helps doctors identify which lung cancer patients are most likely to benefit from immunotherapy, improving treatment decisions.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly help patients. The AI model may not work well in all patient groups or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY NON-SMALL CELL CARCINOMA OF LUNG

AI could predict who lives longer after lung cancer immunotherapy

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions